Millennium Management
MLTX icon

Millennium Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Millennium Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.7M Sell
576,092
-226,630
-28% -$3.75M ﹤0.01% 2110
2025
Q4 		$10.6M Buy
802,722
+713,550
+800% +$8.42M ﹤0.01% 2207
2025
Q3 		$639K Buy
+89,172
New +$4.65M ﹤0.01% 4926
2025
Q2 		– Sell
-344,320
Closed -$13.5M – 6169
2025
Q1 		$13.5M Buy
+344,320
New +$14.8M 0.01% 1894
2024
Q4 		– Sell
-51,267
Closed -$2.62M – 6253
2024
Q3 		$2.58M Sell
51,267
-165,697
-76% -$7.76M ﹤0.01% 3466
2024
Q2 		$9.54M Buy
216,964
+195,989
+934% +$8.3M ﹤0.01% 2114
2024
Q1 		$1.05M Sell
20,975
-53,133
-72% -$2.88M ﹤0.01% 4251
2023
Q4 		$4.48M Buy
74,108
+43,578
+143% +$2.25M ﹤0.01% 2885
2023
Q3 		$1.74M Sell
30,530
-161,874
-84% -$8.94M ﹤0.01% 3690
2023
Q2 		$9.81M Buy
192,404
+157,333
+449% +$4.23M ﹤0.01% 2047
2023
Q1 		$750K Buy
+35,071
New +$590K ﹤0.01% 4329
2022
Q3 		– Sell
-28,090
Closed -$147K – 7335
2022
Q2 		$147K Sell
28,090
-120,135
-81% -$755K ﹤0.01% 5777
2022
Q1 		$1.65M Buy
148,225
+92,490
+166% +$920K ﹤0.01% 4060
2021
Q4 		$551K Hold
55,735
– – ﹤0.01% 4958
2021
Q3 		$555K Hold
55,735
– – ﹤0.01% 5254
2021
Q2 		$577K Buy
55,735
+35,735
+179% +$363K ﹤0.01% 5170
2021
Q1 		$204K Hold
20,000
– – ﹤0.01% 5486
2020
Q4 		$227K Buy
+20,000
New +$212K ﹤0.01% 4737

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management's MLTX Position: Q1 2026 in Review

Millennium Management reduced its MoonLake Immunotherapeutics (MLTX) stake by 28% in Q1 2026, selling an estimated $3.75M and leaving 576,092 shares worth $10.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2110.

Millennium Management first reported a position in MLTX in Q4 2020 and has held it in 18 quarters since. The position peaked at $13.5M in Q1 2025. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Millennium Management held 576,092 shares of MoonLake Immunotherapeutics worth $10.7M as of Q1 2026.
  • Millennium Management sold 226,630 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $3.75M.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2110 holding.
  • Millennium Management first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 18 quarters since.
  • Millennium Management's MoonLake Immunotherapeutics position peaked at $13.5M in Q1 2025.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.